GlassScriptPhysician profile
Clarence Dunn
NPI 1770673568
$6,060.19
in general payments reported to CMS, 2019-2025
29 companies · $955 in 2025
The $955 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $527 · 2021: $1,166 · 2022: $924 · 2023: $891 · 2024: $895 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.89 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,494.77 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,176.54 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Braintree Laboratories, INC. | $397.80 | 2019-2023 | Suflave, Sutab |
| Olympus America INC. | $337.82 | 2020-2024 | Visiglide |
| Ardelyx, INC. | $290.69 | 2024-2025 | Ibsrela |
| Redhill Biopharma INC. | $197.98 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $193.00 | 2019-2024 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $172.55 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $159.27 | 2021-2023 | Dificid |
| Janssen Biotech, INC. | $120.10 | 2021-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $83.71 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $70.20 | 2022-2025 | |
| Qol Medical, LLC | $54.76 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $47.43 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $42.50 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $41.43 | 2021-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $37.72 | 2021-2022 | |
| Genzyme Corporation | $37.27 | 2023-2025 | |
| Alfasigma USA, INC. | $32.66 | 2020 | |
| Celgene Corporation | $27.10 | 2022 | |
| Aimmune Therapeutics, INC. | $18.37 | 2025 | Zenpep |
| Celltrion USA INC. | $13.71 | 2024 | Vegzelma |
| Allergan, INC. | $12.81 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.